SIRPA: A Potential Drug Target for Pain and Inflammation (G140885)

Target Name: SIRPA

NCBI ID: G140885

SIRPA

SIRPA: A Potential Drug Target for Pain and Inflammation

SIRPA (Inhibitory receptor SHPS-1) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a type of inhibitory receptor that is involved in the regulation of pain and inflammation.

Recent studies have identified SIRPA as a potential drug target for the treatment of various diseases, including chronic pain, neurodegenerative diseases, and autoimmune disorders. This is due to SIRPA's unique mechanism of action, which involves the regulation of pain and inflammation by inhibiting the release of certain neurotransmitters that can cause pain and inflammation.

One of the key benefits of targeting SIRPA is its potential to reduce the risk of side effects associated with traditional pain medications. Many pain medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), have been associated with significant side effects, such as stomach ulcers, bleeding, and liver damage. By inhibiting the release of pain-causing neurotransmitters, SIRPA has the potential to reduce the risk of these side effects and improve the quality of life for patients.

Another potential benefit of targeting SIRPA is its potential to treat various neurological disorders, including chronic pain, neurodegenerative diseases, and autoimmune disorders. For example, SIRPA has been shown to be involved in the regulation of pain and inflammation in conditions such as multiple sclerosis, parkinson's disease, and Alzheimer's disease. By targeting SIRPA, researchers and clinicians may be able to develop more effective treatments for these conditions.

In addition to its potential as a drug target, SIRPA is also being investigated as a potential biomarker for various diseases. The SHPS-1 gene is located on chromosome 11 and is responsible for the production of the SIRPA protein. By analyzing the expression of SIRPA, researchers may be able to develop new diagnostic tests for diseases associated with SIRPA dysfunction.

SIRPA is also a potential target for drug development due to its unique mechanism of action. The release of certain neurotransmitters, such as pain-causing neurotransmitters, is regulated by the SIRPA protein. By inhibiting the release of these neurotransmitters, SIRPA has the potential to reduce the risk of side effects associated with traditional pain medications. This may make SIRPA an attractive target for the development of new pain medications that are free from traditional side effects.

In conclusion, SIRPA is a protein that is expressed in various tissues throughout the body and is involved in the regulation of pain and inflammation. Its unique mechanism of action makes it a potential drug target for the treatment of various diseases, including chronic pain, neurodegenerative diseases, and autoimmune disorders. In addition, SIRPA is also being investigated as a potential biomarker for various diseases and may be an attractive target for drug development due to its unique mechanism of action.

Protein Name: Signal Regulatory Protein Alpha

Functions: Immunoglobulin-like cell surface receptor for CD47. Acts as docking protein and induces translocation of PTPN6, PTPN11 and other binding partners from the cytosol to the plasma membrane. Supports adhesion of cerebellar neurons, neurite outgrowth and glial cell attachment. May play a key role in intracellular signaling during synaptogenesis and in synaptic function (By similarity). Involved in the negative regulation of receptor tyrosine kinase-coupled cellular responses induced by cell adhesion, growth factors or insulin. Mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47 binding prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Plays a role in antiviral immunity and limits new world arenavirus infection by decreasing virus internalization (By similarity). Receptor for THBS1 (PubMed:24511121). Interaction with THBS1 stimulates phosphorylation of SIRPA (By similarity). In response to THBS1, involved in ROS signaling in non-phagocytic cells, stimulating NADPH oxidase-derived ROS production (PubMed:24511121)

The "SIRPA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SIRPA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets